Page last updated: 2024-10-15

sifuvirtide

Description

sifuvirtide: a linear 36-amino acid residues anti-HIV peptide; MW 4727 Da; amino acid sequence in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID156963683
MeSH IDM0492288

Synonyms (1)

Synonym
sifuvirtide

Research Excerpts

Overview

Sifuvirtide (SFT) is a peptide-based HIV-1 fusion inhibitor approved for phase III clinical trials in China. It is a gp41 based peptide that inhibits HIV- 1 fusion with the host cells and is currently under clinical trials.

ExcerptReference
"Sifuvirtide (SFT) is a peptide-based HIV-1 fusion inhibitor approved for phase III clinical trials in China."( Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
Chong, H; Cui, S; Ding, X; He, Y; Liu, Z; Wei, H; Wu, X; Yu, D; Zhu, Y, 2018
)
"Sifuvirtide is a gp41 based peptide that inhibits HIV-1 fusion with the host cells and is currently under clinical trials. "( The role of blood cell membrane lipids on the mode of action of HIV-1 fusion inhibitor sifuvirtide.
Castanho, MA; Freitas, T; Matos, PM; Santos, NC, 2010
)
"Sifuvirtide (SFT) is an electrostatically constrained α-helical peptide fusion inhibitor showing potent anti-HIV activity, good safety, and pharmacokinetic profiles, and it is currently under phase II clinical trials in China. "( Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.
Chong, H; Cui, S; He, Y; Waltersperger, S; Wang, M; Yao, X; Zhang, C, 2012
)
"Sifuvirtide is a proven effective HIV-1 entry inhibitor and its safety profile has been established for systemic administration. "( Efficacy, stability, and biosafety of sifuvirtide gel as a microbicide candidate against HIV-1.
Ben, Y; Jiang, S; Li, L; Xu, J; Yuan, S; Zhang, X, 2012
)

Toxicity

ExcerptReference
" These results suggest that sifuvirtide gel is an effective, safe and stable product, and should be further tested as a vaginal or rectal microbicide in pre-clinical model or clinical trial for preventing HIV sexual transmission."( Efficacy, stability, and biosafety of sifuvirtide gel as a microbicide candidate against HIV-1.
Ben, Y; Jiang, S; Li, L; Xu, J; Yuan, S; Zhang, X, 2012
)

Pharmacokinetics

ExcerptReference
"An on-line SPE-LC/MS/MS approach was established for peptide pharmacokinetic studies."( Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro.
Dai, SJ; Dou, GF; Liang, Q; Liu, DS; Liu, XW; Qiang, XH; Song, HF; Tang, ZM; Yang, LM; Zheng, YT, 2005
)
"5 h for 20 mg group; the mean Cmax of last dose was 498 ± 54 ng/mL for 10 mg group and 897 ± 136 ng/mL for 20 mg group."( Pharmacokinetics of sifuvirtide in treatment-naive and treatment-experienced HIV-infected patients.
Che, J; Chen, X; Cheng, Y; Dong, T; Meng, Q; Qian, X; Tong, B, 2014
)

Bioavailability

ExcerptReference
"25-2 h, and the absolute bioavailability was 49%+/-13%."( Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro.
Dai, SJ; Dou, GF; Liang, Q; Liu, DS; Liu, XW; Qiang, XH; Song, HF; Tang, ZM; Yang, LM; Zheng, YT, 2005
)

Dosage Studied

ExcerptReference
" These findings suggest that application of enfuvirtide and sifuvirtide in combination may improve their efficacy and resistant profile, leading to a reduction of the dosage and frequency of drug use."( Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors.
Jiang, S; Lu, H; Pan, C; Qi, Z, 2009
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (25.00)29.6817
2010's18 (75.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (8.33%)5.53%
Reviews2 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]